|
The document discusses a liver study conducted on Washington Works employees exposed to C-8 (PFOA), concluding that there is no evidence of occupationally related health problems among workers, despite some indications of elevated fluoride levels.
|
— |
AR226-3453
|
pBOBXnq8d92Rj5n7qQ2w7ENVa |
4 |
|
The document reviews personnel air monitoring and blood data related to C-8 (PFOA) exposure at Washington Works, demonstrating a correlation between air levels, skin exposure, and blood levels, with significant findings indicating that skin contact contributes to elevated blood levels.
|
— |
AR226-3452
|
63e24RgLa2pqjqdbKQqjDZdg |
8 |
|
The document is a summary of C-8 (PFOA) blood level data for employees and a retiree from DuPont, indicating that while some individuals showed increases in blood levels, the overall trend suggests a decrease, particularly for a retiree whose levels are estimated to decrease at a rate of 0.15 ppm per year.
|
— |
AR226-3450
|
MGzoVXXbVnwXg1LLJnpraa5Qx |
18 |
|
This document contains blood test results for C-8 (PFOA) levels from 3M and NMS, with various numerical values listed alongside control numbers.
|
— |
AR226-3454
|
kDoJoDbBL4Ver6N8p58Ej1aRB |
3 |
|
The memorandum reports on a voluntary blood testing program for C-8 (PFOA) conducted in 1997, where twelve individuals were tested with results ranging from 0.00 to 0.56 ppm, concluding that the findings do not warrant concern or action.
|
— |
AR226-3455
|
jxyVJ52qpRkG9nYZpjx5Nxm2 |
2 |
|
The document reports on a 1995 study of blood levels of ammonium perfluorooctanoate (C-8) among employees potentially exposed to the substance, indicating that no individuals had levels exceeding 5 ppm, with job-specific averages ranging from 0.5 to 3.5 ppm, and highlights the persistence of C-8 in the blood and the need for ongoing monitoring
|
— |
AR226-3456
|
N2mNvgRKz57bbkgKq1LO39DzQ |
2 |
|
The document discusses preliminary blood test results for C-8 (PFOA) levels among employees at DuPont's Washington Works, revealing that four individuals had levels exceeding 5 ppm, prompting an investigation into a cluster of high results among Granular Polykettle Operators.
|
— |
AR226-3457
|
4QQqV9RnLVOpgkqOOnZgZegpG |
3 |
|
The document presents blood test results for pensioners exposed to C-8 (PFOA) from DuPont, showing a decrease in blood concentration levels from 1995 to 2000, with an estimated half-life of about four years.
|
— |
AR226-3458
|
8RDbNRJxX3nJJpgvR1E7oVmxk |
3 |
|
This document appears to be a summary of blood levels of PFOA among various job classifications from 1989 to 2000, highlighting significant changes and limitations in the data analysis due to small sample sizes and employee job transfers.
|
— |
AR226-3459
|
8VgLdnV32VjJenZvvLrE27NQZ |
9 |
|
This document presents half-life results for various samples, detailing concentrations (PPM) and corresponding dates, along with calculated average half-lives and standard deviation.
|
— |
AR226-3462
|
8RXv4vJdyaJO0pg2Dka6QG9zB |
2 |
|
The document presents blood concentration data for perfluorooctanoic acid (PFOA) in employees from 1984 to 1985, showing average levels and variations across different job categories.
|
— |
AR226-3461
|
x11GorkVNk4wvvoNbJr4YaL81 |
2 |
|
The document presents blood sample analysis results for PFOA levels from employees, indicating an average concentration of 2.49 ppm with a maximum of 11.1 ppm.
|
— |
AR226-3463
|
4EqwmDBKDDnV71XRwkZ4ba9a |
2 |
|
Unreadable document.
|
— |
AR226-3464
|
jd0yMagkz7nYD67bo91r74QR |
2 |
|
The document discusses the presence of C-8 (PFOA) in the blood of DuPont workers, highlighting its persistence, the normal liver function of those affected, and the ongoing voluntary blood testing program to monitor exposure levels and address concerns raised by previous data reviews.
|
— |
AR226-3465
|
6B34MLyGDE4DBaQV8awxYoMyE |
11 |
|
In May 1978, 3M informed Du Pont of the presence of organic fluorocompounds, including PFOA, in the blood of employees exposed to fluorosurfactants, prompting Chambers Works to initiate a program to assess exposure levels and health effects, which found that while employee blood levels were slightly elevated compared to a control group, they remained below 1 ppm and no adverse
|
— |
AR226-3467
|
e1vkQBeeJgjd35qNz9m6M5Q74 |
3 |
|
The document is a technical report from E.I. DuPont de Nemours & Company detailing a study on the kinetics of sorption and elimination of perfluorinated surfactants, specifically perfluorooctanoic acid, in rat blood following inhalation exposure, indicating that the concentration of organic fluorine in blood increases with inhaled concentration and elimination follows first-order kinetics.
|
— |
AR226-3466
|
6RnRxLnNMNYY8z6wZOxR1bDQm |
29 |
|
The document presents results from a blood study of Chambers Works employees, indicating that their levels of organic fluorine, including PFOA, are within normal ranges and do not show elevated levels compared to a Wilmington control group.
|
— |
AR226-3469
|
wgZvQkqBpJL9BdaaOz9v86wVD |
6 |
|
The document reports on a study analyzing health data from employees exposed to a surfactant, indicating that the exposed group had significantly higher incidences of allergic, endocrine, metabolic, mental, and skin disorders, while the control group had more incidents of circulatory diseases, with abnormal liver function tests being higher but not statistically significant in the exposed group.
|
— |
AR226-3468
|
j79ExzgONQpmGOQB7vkBZxbp |
14 |
|
The document summarizes a 1978-79 study conducted by DuPont on organic fluorine levels in the blood of Chambers Works employees potentially exposed to fluorosurfactants, which included air monitoring and blood analysis to assess exposure and health effects.
|
— |
AR226-3470
|
K6LJp24Nw2z1w4DaYn5aZm102 |
2 |
|
The document summarizes blood data from employees at Chambers Works and Wilmington Controls, indicating that a review of medical records from potentially exposed workers to fluorochemicals, including C-8 (PFOA), did not suggest adverse health effects, while presenting various organic fluorine levels detected in blood samples over different years.
|
— |
AR226-3471
|
R2Bve2x69O0o5bqJ3D4GDY6Dz |
3 |
|
DuPont conducted a study in 1978-1979 to monitor total organic fluorine (TOF) levels in the blood of workers at its Chambers Works plant, finding levels ranging from none detected to 0.38 ppm in comparison to higher levels reported in workers from another company, despite no direct handling of the same chemicals.
|
— |
AR226-3472
|
L7VpYqk9kMKmDVDk3L8Nd8b7 |
3 |
|
This document summarizes the monitoring data for PFOA concentrations in human blood serum from workers at the DuPont Chambers Works site in 2004, detailing various statistics such as mean, median, and maximum concentrations across different job titles.
|
— |
AR226-3473
|
r6q7JMdg84e876RMDQZE1gnmG |
4 |
|
The document presents baseline monitoring results for perfluorinated compounds, specifically detailing various sample concentrations from First Chemical Company in Pascagoula, MS, with results ranging from 0.989 ppb to 12.1 ppb.
|
— |
AR226-3474
|
8Vn8em7YmN8qVbKgNN7RRLamk |
4 |
|
The document discusses blood monitoring for PFOA at the former Atofina manufacturing site, highlighting the need for more information before agreeing to participate in the monitoring campaign and detailing preliminary discussions about analytical methods and detection limits for PFOA and PFOS.
|
— |
AR226-3476
|
byzZV2YzgZZD8NygZyjDmbyGO |
4 |
|
The document presents findings from blood sampling conducted at various production sites in France, indicating that PFOA levels in the general population are significantly lower than those found in 3M operators, with a notable comparison of PFOA toxicity and exposure limits.
|
— |
AR226-3475
|
pdnL8Q0EQMX8bNm4BD1onp0a |
13 |
|
This document summarizes the monitoring data of Perfluorooctanoic Acid (PFOA) in whole blood samples collected from workers at DuPont's Washington Works facility in Parkersburg, West Virginia, in 1979, detailing concentrations across various job roles with a maximum concentration of 28.4 ppm.
|
— |
AR226-3460
|
ypJwaYegZ6L947q3pv4Kdoe2r |
159 |